Glaucoma, Open-angle, Ocular Hypertension
Conditions
Brief summary
This is a Phase I, multi-center, randomized, adaptive, investigator/patient-masked, placebo-controlled, parallel multiple-ascending dose study (Part A) with an extension including up to two selected doses from Part A and latanoprost 0.005% as active comparator (Part B).
Interventions
DRUG0.01% RO7058584
Once daily morning administration for 7 days
DRUG0.1% RO7058584
Once daily morning administration for 7 days
DRUG1% RO7058584
Once daily morning administration for 7 days
DRUGMatching Placebo
Once daily morning administration for 7 days
Once daily morning or evening dosing
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* 18 to 90 years of age inclusive, at the time of signing the informed consent form * Confirmed diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma (POAG) in both eyes as determined by the investigator at screening * Treatment-naïve participants or participants who are able to safely stop their Intraocular pressure (IOP)-lowering medication(s) prior to randomization according to the required minimum washout periods * At baseline visit, IOP ≥ 24 millimeters of mercury (mmHg) in the morning (8:00 AM ± 1h) and ≥ 22 mmHg in the afternoon (2:00 PM ± 1h) measurement in the same eye and ≤ 34 mmHg at all timepoints in both eyes * Best corrected logarithm of the minimum angle of resolution (logMAR) visual acuity score of 0.7 or better in each eye as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity test at screening * Central corneal thickness (pachymetry) measurement 450 to 620 micrometers (μm) in both eyes at screening * Cup-to-disc ratio ≤ 0.8 (both eyes) at screening * Anterior chamber angle is open and non-occludable (both eyes) as confirmed by the investigator by gonioscopy examination at screening
Exclusion criteria
* Advanced visual field defects * Other forms of glaucoma than POAG or OHT * Any abnormality preventing reliable applanation tonometry * Any clinically significant corneal scarring, haze or opacity * Uncooperativeness of the participant that restricts adequate examination of IOP, ocular fundus or anterior chamber * Any presence or history of uveitis or other history of any ocular inflammatory disease. * History or signs of penetrating ocular trauma * Risk of visual field or visual acuity worsening in either eye as a consequence of glaucoma progression or consequence of participation in the trial or any other ocular disease, according to the investigator's best judgment * History of any glaucoma surgery * History of refractive surgery * Any other intra-ocular surgery within six months of screening * Any active ocular disease requiring treatment. * Use of any listed prohibited medications * Current enrollment or past participation within the last 30 days before the screening visit in any other clinical study involving an investigational study treatment or any other type of medical research * Any participant who is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff thereof, directly involved in the conduct of the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Mean Intraocular pressure (IOP) After 7 Days of Study Drug Administration | 7 days | IOP will be assessed by Goldman Applanation tonometry. |
| Incidence, Severity, and Causal Relationship of Ocular and Systemic Adverse Events (AEs) | Up to 12 weeks | An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
| Incidence of Abnormal Laboratory Findings | Up to 12 weeks | — |
| Incidence of Blood Pressure Abnormalities | Up to 12 weeks | — |
| Incidence of Pulse Rate Abnormalities | Up to 12 weeks | — |
| Incidence of Electrocardiogram (ECG) Findings | Up to 12 weeks | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax of RO7058584 | Up to Day 8 | Cmax is the maximum observed plasma concentration. |
| Tmax of RO7058584 | Up to Day 8 | Tmax is the time to maximum observed plasma concentration. |
| Ctrough of RO7058584 | Up to Day 8 | Ctrough is the concentration at the end of a dosing interval before the next dose administration. |
| AUC0-24h of RO7058584 | Up to Day 8 | AUC0-24h is the area under the plasma concentration versus time curve (AUC) from Time 0 to 24 h post-dose. |
| Change From Baseline in Mean Intraocular pressure (IOP) at Matched Clock-Times After 7 Days of Study Drug Administration | 7 days | IOP will be assessed by Goldmann Applanation tonometry |
Countries
United States
Outcome results
None listed